Association between CT-detected brain metastases and EGFR mutation status in non–small cell lung cancer

Darayani Dina Dharma; Sri Asriyani; Junus Baan; Andi Alfian Zainuddin; Harun Iskandar; Muhammad Ilyas; Amalia Yamin

doi:10.23750/abm..18452

Authors

Darayani Dina Dharma Department of Radiology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Sri Asriyani Department of Radiology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Junus Baan Department of Radiology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Andi Alfian Zainuddin Department of Public Health and Community Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Harun Iskandar Department of Pulmonology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Muhammad Ilyas Department of Radiology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Amalia Yamin Department of Anatomic Pathology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

Keywords:

brain metastasis, non‑small cell lung carcinoma, EGFR, head CT scan

Abstract

Background and aim: To evaluate the relationship between head multidetector computed tomography (MDCT) features of brain metastases and epidermal growth factor receptor (EGFR) mutation status in patients with histologically confirmed non‑small cell lung carcinoma (NSCLC).

Methods: In this retrospective cross‑sectional study, medical records and PACS imaging from Dr. Wahidin Sudirohusodo General Hospital (January 2022–May 2025) were screened. Of 1,096 patients with lung tumors, 33 met inclusion criteria (histopathologically confirmed NSCLC, available EGFR result, and evaluable head MDCT demonstrating brain metastasis). Head MDCT scans were reviewed for number of lesions, rim enhancement, peritumoral vasogenic edema, hemorrhagic component, leptomeningeal disease and calcification.

Results: Patients were classified as EGFR‑mutant (n = 14) or EGFR‑wild‑type (n = 19). The cohort was 60.6% male, most patients were aged 56–65 years, and 51.5% were never‑smokers. Rim enhancement on MDCT differed by EGFR status: EGFR‑wild‑type lesions more often demonstrated rim enhancement (94.7% of wild‑type vs. 42.9% of mutant lesions), while EGFR‑mutant lesions more often lacked rim enhancement (57.1%); this association was statistically significant (p = 0.002). No significant relationships were found between EGFR status and number of lesions, vasogenic edema, hemorrhagic change, leptomeningeal involvement or calcification (all p > 0.05). NSCLC histologic subtype and EGFR mutation subtype analyses similarly showed no statistically significant associations with the assessed MDCT features.

Conclusions: This study showed rim enhancement on head MDCT was associated with EGFR status, being more frequent in EGFR‑wild‑type tumors; other MDCT features were not significantly related to EGFR mutation. Larger, prospective studies using MRI and comprehensive molecular profiling are warranted to validate these observations.

References

1. Andarini S, Syahruddin E, Aditya N, Zaini J, Kurniawan FD, Ermayanti S, et al. Indonesian Society of Respirology (ISR) Consensus Statement on Lung Cancer Screening and Early Detection in Indonesia. Jurnal Respirologi Indonesia. 2023;43(2): 144–150. https://doi.org/10.36497/jri.v43i2.455.

2. Shao J, Li J, Song L, He Q, Wu Y, Li L, et al. The number of brain metastases predicts the survival of non‐small cell lung cancer patients with EGFR mutation status. Cancer Reports. 2022;5(9): e1550. https://doi.org/10.1002/cnr2.1550.

3. Schroeder T, Bittrich P, Kuhne JF, Noebel C, Leischner H, Fiehler J, et al. Mapping distribution of brain metastases: does the primary tumor matter? Journal of Neuro-Oncology. 2020;147(1): 229–235. https://doi.org/10.1007/s11060-020-03419-6.

4. Hsu F, De Caluwe A, Anderson D, Nichol A, Toriumi T, Ho C. EGFR mutation status on brain metastases from non-small cell lung cancer. Lung Cancer. 2016;96: 101–107. https://doi.org/10.1016/j.lungcan.2016.04.004.

5. Li L, Luo S, Lin H, Yang H, Chen H, Liao Z, et al. Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer. Journal of Thoracic Disease. 2017;9(8): 2510–2520. https://doi.org/10.21037/jtd.2017.07.57.

6. Iuchi T, Shingyoji M, Itakura M, Yokoi S, Moriya Y, Tamura H, et al. Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations. International Journal of Clinical Oncology. 2015;20(4): 674–679. https://doi.org/10.1007/s10147-014-0760-9.

7. Sekine A, Kato T, Hagiwara E, Shinohara T, Komagata T, Iwasawa T, et al. Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: Distinguishing influence of exon 19 deletion on radiographic features. Lung Cancer. 2012;77(1): 64–69. https://doi.org/10.1016/j.lungcan.2011.12.017.

8. Baek MY, Ahn HK, Park KR, Park HS, Kang SM, Park I, et al. Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer. The Korean Journal of Internal Medicine. 2018;33(1): 168–175. https://doi.org/10.3904/kjim.2015.158.

9. Han G, Bi J, Tan W, Wei X, Wang X, Ying X, et al. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis? Oncotarget. 2016;7(35): 56998–57010. https://doi.org/10.18632/oncotarget.10933.

10. Winslow N, Boyle J, Miller W, Wang Y, Geoffroy F, Tsung AJ. Development of brain metastases in non-small-cell lung cancer: high-risk features. CNS Oncology. 2024;13(1): 2395804. https://doi.org/10.1080/20450907.2024.2395804.

11. Pinto JA, Vallejos CS, Raez LE, Mas LA, Ruiz R, Torres-Roman JS, et al. Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy? ESMO Open. 2018;3(3): e000344. https://doi.org/10.1136/esmoopen-2018-000344.

12. Waqar SN, Samson PP, Robinson CG, Bradley J, Devarakonda S, Du L, et al. Non–small-cell Lung Cancer With Brain Metastasis at Presentation. Clinical Lung Cancer. 2018;19(4): e373–e379. https://doi.org/10.1016/j.cllc.2018.01.007.

13. Yan DF, Yan SX, Yang JS, Wang YXJ, Sun XL, Liao XB, et al. Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature. BMC Cancer. 2010;10(1): 49. https://doi.org/10.1186/1471-2407-10-49.

14. Jao K, Tomasini P, Labbe C, Doherty M, Shepherd FA. Diffuse Hemorrhagic Brain Metastases in an ALK Fusion Positive Patient on Crizotinib. Journal of Thoracic Oncology. 2015;10(6): 965–966. https://doi.org/10.1097/JTO.0000000000000403.

15. Tran TT, Mahajan A, Chiang VL, Goldberg SB, Nguyen DX, Jilaveanu LB, et al. Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy. Journal for ImmunoTherapy of Cancer. 2019;7(1): 200. https://doi.org/10.1186/s40425-019-0684-z.

16. Zhu J quan, Zhong W zhao, Zhang G chun, Li R, Zhang X chao, Guo A lin, et al. Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. Cancer Letters. 2008;265(2): 307–317. https://doi.org/10.1016/j.canlet.2008.02.064.

17. Fang MM, Cheng JT, Chen YQ, Lin XC, Su JW, Wu YL, et al. Molecular features and clinical outcomes of EGFR-mutated, MET-amplified non-small-cell lung cancer after resistance to dual-targeted therapy. Therapeutic Advances in Medical Oncology. 2024;16: 17588359241234504. https://doi.org/10.1177/17588359241234504.

18. Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, et al. Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers. Lung Cancer. 2015;88(1): 108–111. https://doi.org/10.1016/j.lungcan.2015.01.020.

19. Ouyang W, Yu J, Zhou Y, Hu J, Huang Z, Zhang J, et al. Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer. BMC Cancer. 2020;20(1): 699. https://doi.org/10.1186/s12885-020-07202-8.

20. Zhao W, Zhou W, Rong L, Sun M, Lin X, Wang L, et al. Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer. Frontiers in Oncology. 2022;12: 912505. https://doi.org/10.3389/fonc.2022.912505.

21. Sunata K, Tani T, Ui T, Irie H, Funatsu Y, Koh H. Remarkable Differences in Calcification between the Primary Tumor and Metastatic Lymph Nodes in a Patient with ALK-Positive Non-Small-Cell Lung Cancer. Oey IF (ed.) Case Reports in Pulmonology. 2022;2022: 1–4. https://doi.org/10.1155/2022/1160000.

22. Matsuzaki T, Ikemura S, Shinozaki T, Iwami E, Nakajima T, Katayama M, et al. Non‑small cell lung cancer with multiple brain metastases remains relapse‑free for more than 13 years: A case report. Molecular and Clinical Oncology. 2021;16(1): 18. https://doi.org/10.3892/mco.2021.2448.

23. Bahrami E, Taheri M, Benam M. Calcified brain metastatic adenocarcinoma: A case report and review of the literature. The Neuroradiology Journal. 2019;32(1): 57–61. https://doi.org/10.1177/1971400918805184.

24. Rebella G, Romano N, Silvestri G, Ravetti JL, Gaggero G, Belgioia L, et al. Calcified brain metastases may be more frequent than normally considered. European Radiology. 2021;31(2): 650–657. https://doi.org/10.1007/s00330-020-07164-2.

25. Nguyen A, Nguyen A, Dada OT, Desai PD, Ricci JC, Godbole NB, et al. Leptomeningeal Metastasis: A Review of the Pathophysiology, Diagnostic Methodology, and Therapeutic Landscape. Current Oncology. 2023;30(6): 5906–5931. https://doi.org/10.3390/curroncol30060442.